CHAPEL HILL, N.C.--(BUSINESS WIRE)--POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, today announced the election of Martin Nicklasson, Ph.D., to its Board of Directors at the Annual Meeting of Shareholders held on June 9, 2011. Dr. Nicklasson has been a senior leader in both large and small pharmaceutical organizations, and has held leadership roles in commercial operations and clinical development. Dr. Nicklasson held various Executive Vice President positions at AstraZeneca Plc. from 1999 to 2007, including Chairman of the Board of Astra Tech AB, a subsidiary of AstraZeneca (2004 to 2007), Executive Vice President, Global Marketing & Business Development (2005 to 2007), Executive Vice President, Global Drug Development (2002 to 2005) and Executive Vice President, Global Gastrointestinal Franchise (1999 to 2002). From 2007 to 2010, Dr. Nicklasson was the President and Chief Executive Officer of Biovitrum AB and Swedish Orphan Biovitrum AB, a publicly listed specialty pharma company. Dr. Nicklasson is currently a Senior Partner at Nicklasson Life Science AB, an independent consultancy and advisory company to the pharmaceutical and biotechnology sector. Dr. Nicklasson serves on the Board of the Stockholm Chamber of Commerce and the Board of the Heart and Lung Foundation of Sweden.
